Development of vaccines based on formulations containing nonionic block copolymers.
In summary, data indicate that nonionic block copolymers in several different delivery formats can effectively enhance antibody responses to a variety of viral, parasite, or bacterial antigens. Polymers have historically been evaluated as polymers alone in aqueous buffer, in oil-in-water and water-in-oil emulsions. Several of those formulations can induce protective antibodies in preerythrocytic or erythrocytic malaria vaccine models or in pneumococcal vaccine models. In those models, protective immunity is associated with the development of IgG2a subclass antibodies. These results tend to indicate that copolymer adjuvant can influence isotype development, possibly by stimulating the appropriate T-cell subsets. Although there are some data suggesting that microfluidized vaccines containing the L121 nonionic block copolymer can induce CTL, equivalent experimental results with larger block polymers, which are effective in induction of greater proportions of IgG2a, have not yet been obtained. Several of the basic formulations with an appropriate copolymer may be suitable for clinical evaluation in conjunction with either current or future subunit antigens. Other formulations containing copolymers may also be suitable for mucosal administration.
Brey
R N
RN
Vaxcel, Inc., Norcross, Georgia 30071, USA.
D000276:Adjuvants, Immunologic; D016503:Drug Delivery Systems; D006801:Humans; D011108:Polymers / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000737:chemistry; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000737:chemistry*
D000276:Adjuvants, Immunologic; D011108:Polymers; D014614:Vaccines, Synthetic